quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation

View original at seekingalpha.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation Earnings Call Insights: Ibotta, Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Low single-digit sequential revenue growth expected in Q2 versus Q1, and slight year-over-year revenue growth expected in Q3

    80% confidence
  • LiveLift is the most sophisticated capability and represents where the industry is heading

    80% confidence
  • There's real emphasis on value among clients and Ibotta is well positioned in terms of the macro environment

    80% confidence
  • Q1 2026 adjusted EBITDA expected in range of $6 million to $8 million, representing about 9% adjusted EBITDA margin at midpoint

    80% confidence
  • Stock-based compensation expense expected to be approximately $10 million higher than 2025

    80% confidence
  • Broad-based sequential progress in year-over-year redemption revenue trends throughout Q4, with LiveLift revenue better than projected and SNAP program contributing incremental revenue

    80% confidence
  • Q4 revenue and adjusted EBITDA are both above the top end of the guidance range, representing an improvement in year-over-year revenue trends compared to Q3

    80% confidence
  • Outperformance attributed to improved execution, core product strengthening, and expansion of LiveLift

    80% confidence
  • LiveLift allows clients to see projected incremental sales and cost per incremental dollar at various intervals during campaigns, enabling better optimization

    80% confidence
  • Average campaign size in LiveLift from companies piloting it is substantially larger than average campaign size in core Ibotta offering from same companies

    80% confidence
  • More offers, better quality offers, and longer duration on network drive more redemptions per redeemer

    80% confidence
  • Q4 revenue and adjusted EBITDA were 7% and 31% above the midpoint of Q3 guidance respectively

    80% confidence
  • Companies added additional budget to same brands and added additional brands into the program

    80% confidence
  • Third-party redeemers grew by almost 3.5 million in Q4, with about one-third from existing publishers

    80% confidence
  • Third-party redeemer growth attributed to new publisher partnerships and innovations in in-store and online awareness

    80% confidence
  • Clients can purchase sales lift studies just as they would for other forms of digital media through partnerships with Circana and ABCS Insights

    80% confidence
  • Q1 2026 revenue expected in range of $78 million to $82 million, representing 5% year-over-year decline at midpoint

    80% confidence
  • LiveLift is a TAM expander with ability to provide ongoing, actionable metrics

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation — Source | Via News | pt.VIA.NEWS